% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • chenghao888us chenghao888us Nov 17, 2006 3:22 PM Flag

    You be the judge

    managment sucks.
    1. NIPENT deal got underpaid.
    2. poor internal control

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I don't know that it is fair to say management sucks. They seem�@to have a strategy - sheedding non-core and lowering OE while moving the top line forward with Dacogen. They did move Dacogen out quickly and effectively once it was given the green light. The aggravation I have is with:

      -very last minute change in the earnings accounting (it was supposed to be a merry christmas)
      -not a great PR machine going for this company

      Overall, it does seem to be moving in the right direction but just think we have lost out on stock price catalysts which is a shame. For me it is coming down to how long is the wait for a payoff and what is the opportunity cost.

      • 1 Reply to kichigai06
      • I agree with you Kichigail06. We lost some momentum...but that's all. If things were not looking very favorable for SUPG, would insiders have exercised 7M in warrants at 4.38 last quarter? If they stay long...I will stay long. The company is conservative...some of the news is out of there hands....MGI and JNJ have to announce it first. That handcuffs them a little...but you have to expect that. The mayne pharma buyout vote may not happen till what news could we see? Think we could trade down to 5.00 again. Near the end of December, I see moving back towards 5.50 as Nipent EU and Mayne buyout get close. Company should get back some momentum, 1st quarter.

8.4950.0000(0.00%)Oct 10 4:00 PMEDT